Methods to identify agents that bind the flap-tip helix of RNA polymerase
The invention provides methods to identify moieties which specifically bind the flap-tip helix of the β subunit of RNA polymerase and to identify inhibitors of the interaction between those moieties and the flap-tip helix.
Latest Patents:
This application claims the benefit of the filing date of U.S. application Ser. No. 60/286,783 filed on Apr. 25, 2001, under 35 U.S.C. § 119(e), the disclosure of which is incorporated by reference herein.
STATEMENT OF GOVERNMENT RIGHTSThis invention was made at least in part with a grant from the Government of the United States (grant GM 38660 from the National Institutes of Health). The Government has certain rights to the invention.
BACKGROUND OF THE INVENTIONDNA, RNA, and regulatory molecules control gene expression through interactions with RNA polymerase (RNAP). RNA polymerase is an evolutionarily conserved, multisubunit enzyme responsible for utilizing a DNA strand as a template and making a complementary RNA molecule in all known organisms. As such, it is central to all gene transcription and must function for the cell to survive.
The transcription cycle can be divided into major phases: promoter engagement, initiation, RNA chain elongation, and termination. Promoter engagement encompasses several steps: promoter location and recognition by the RNA polymerase holoenzyme (core enzyme complexed with one of several σ factors), initial and reversible binding of RNA polymerase to duplex promoter DNA (closed complex formation), and formation of an open complex in which about 12 bp of DNA, including the transcription start site, are melted. At least four important intrinsic inputs affect promoter engagement: the hexamer centered at position −10 upstream from the transcription start site (−10 region), the hexamer at position −35 (−35 region), the region of DNA between these two elements (spacer region), and a region located between −40 and −60 (the UP element).
The rates at which these steps occur are dictated by both extrinsic and intrinsic interactions. Extrinsic inputs include protein-protein contacts made by activators and repressors that bind in the vicinity of the promoter DNA and can modify the rates of either closed- or open-complex formation or promoter escape. Intrinsic contacts are made by the σ subunit of RNA polymerase to the −10 and −35 regions of the DNA and sometimes by the α-subunit C-terminal domain to the UP element (Ross et al., 1993).
After the open complex has bound the initiating NTPs, it becomes an initial transcription complex and can follow several alternative reaction pathways: (i) the synthesis and release of short (2 to 8 nucleotides [nt]) RNA transcripts (abortive initiation); (ii) reiterative synthesis resulting in homopolymer extensions of the initial RNA transcripts (stuttering); and (iii) release of σ, translocation away from the promoter, and formation of a transcription elongation complex (TEC) with loss of upstream DNA contacts, usually when the transcript is 8 to 9 nt in length (promoter escape).
Once RNA polymerase converts from initial transcription complex to TEC (i.e., escapes the promoter), it becomes stably associated with the RNA and DNA chains and can elongate the RNA chain 30 to 100 nt/sec in vivo. Two distinct types of translocations in the TEC must occur to allow this rapid movement; (i) translocation of the RNA 3′ end from position i+1 to i in the active site (the 3′-terminal nucleotide is the index position) as successive nucleotides are added and (ii) translocation of DNA and RNA chains through RNA polymerase (RNA and DNA translocation).
RNA chain elongation is punctuated by certain sites where nucleotide addition is slowed by pause, arrest, and termination signals. Pause signals cause. RNA polymerase to isomerize from the rapidly elongating TEC to alternative conformations in which RNA chain extension is reversibly inhibited (by factors of 102 to 104). Termination signals cause the release of RNA and DNA and can be positively or negatively regulated by a variety of extrinsic inputs.
When RNA polymerase encounters a termination signal, RNA polymerase stops adding nucleotides to the RNA, separates the DNA-RNA hybrid, releases the newly synthesized transcript, and dissociates from the DNA template. Three types of termination signals for bacterial RNA polymerase have been described: (i) intrinsic terminators (ρ-independent terminators) which require a stable RNA hairpin formed 7 to 9 nt from the terminated RNA 3′ end and immediately followed by at least 3 U residues, but no extrinsic factors (reviewed in Platt, 1997; Richardson et al., 1996; Roberts, 1996; Uptain et al., 1997); (ii) ρ-dependent terminators, which depend on the presence of p factor, a hexameric RNA-binding protein with ATPase activity (reviewed in Platt, 1997; Richardson et al., 1996); and (iii) persistent RNA-DNA hybrid terminators at which pairing of nascent RNA to the template just upstream from the TEC dissociates a complex containing 3′-proximal U-rich RNA (Tomizawa et al., 1997).
E. coli NusA is a 55-kDa acidic protein that interacts with ρ, λ N, and RNA through one or more interaction regions and RNA polymerase through contacts to the α-subunit C-terminal domain and either β′ or β (Liu et al., 1996; Richardson et al., 1996). NusA enhances both pausing and p-independent termination in the absence of other cellular or phage proteins, is found in all prokaryotes and archaebacteria sequenced to date, and is essential in E. coli unless ρ activity is reduced by a mutation (Zheng et al., 1994).
A universal feature of RNA polymerases is a regulated conversion from an initiating form that holds the RNA weakly, to an elongating form where the enzyme holds RNA tightly during RNA synthesis, and then back to a terminating form that releases RNA. The molecular basis of the switch from initiation to elongation to termination is unknown. However, conservation from bacteria to humans of RNA polymerase's core subunit composition (β,βα2 in bacteria), amino-acid sequences, three-dimensional structure, and contacts to DNA and RNA suggest that the switch will be similar for all multisubunit RNA polymerases (Zhang et al., 1999; Cramer et al., 2000; Korzheva et al., 2000).
A nascent RNA hairpin can terminate transcription by bacterial RNA polymerase if the hairpin includes the 3-5 nt usually found in the RNA exit channel and disrupts at least one base pair (bp) of the about 8-bp nascent RNA:template DNA hybrid that is present in stable TECs (Nudler et al., 1997; Sidorenkov et al., 1998; Artsimovitch and Landick, 1998; Yarnell and Robert, 1999). Similar RNA hairpins can also pause, rather than terminate, transcription when they form more upstream but near the RNA:DNA hybrid, rather than invade it. Both hairpin-dependent pausing and termination can be enhanced by the universal bacterial protein NusA (Chan and Landick, 1993; Sigmund and Morgan, 1988).
Two models can explain hairpin effects on transcription (Korzheva, 2000; Yarnell and Roberts, 1999; Farnham and Platt, 1980; Yager and von Hippel, 1991; Gusarov and Nudler, 1999; Mooney and Landick, 1999; Davenport et al., 2000; Artsimovitch and Landick, 2000). In the rigid-body model, a pause or terminator hairpin begins forming when only its loop and upper stem have emerged from the exit channel and then pulls RNA through the channel and away from the active site to avoid steric clash with a rigid RNA polymerase as the lower stem pairs. This partially unwinds the RNA:DNA hybrid and moves RNA polymerase forward without nucleotide addition (the hybrid is wedged against the upstream edge of the active-site cleft in a TEC; see
As transcription is central to gene regulation, a better understanding of the transcription process and the cellular factors which interact during transcription could lead to the identification of specific inhibitors of transcription. Thus, what is needed is a method to determine what factors specifically interact with portions of RNA polymerase during transcription. What is also needed is a method to identify agents that specifically inhibit those interactions.
SUMMARY OF THE INVENTIONThe invention provides a method to identify agents that specifically inhibit the interaction of moieties, including but not limited to prokaryotic cellular proteins, e.g., transcription factors or subunits of RNA polymerase such as the β′ subunit, nucleic acid aptamers and peptide aptamers, with the flap-tip helix of the β subunit of core RNA polymerase. The flap domain of the β subunit was identified from the crystallized structure of Thermus aquaticus (Zhang et al., 1999) RNA polymerase. At the upper most tip of this flap is a domain termed the flap-tip helix because of its helical structure. As described hereinbelow, a short α-helix at the tip of the flap-like domain that covers the RNA exit channel of RNA polymerase contacts a nascent RNA stem-loop structure (hairpin) that inhibits transcription, and this flap-tip helix is required for activity of the regulatory protein NusA. In particular, a short nine amino acid segment deletion or alternatively mutation of four hydrophobic amino acids within the flap-tip helix, prevents the action of the a initiation factors and the elongation factor NusA. It is highly likely that the flap-tip helix contacts the main body of RNA polymerase during RNA chain elongation, thus sequestering the exiting nascent RNA chain under the closed flap domain. During initiation, the flap-tip helix instead appears to contact σ to open the flap domain. At pause and termination sites, NusA may help reopen the flap domain through a contact to the flap-tip helix. Protein-RNA crosslinking, molecular modeling, and effects of alterations in RNA polymerase and RNA all suggest that a tripartite interaction of RNA polymerase, NusA, and the hairpin inhibits nucleotide addition in the active site, which is located 65 Å away. These findings favor an allosteric model for regulation of transcript elongation.
As also described hereinbelow, expression of β subunits containing flap-tip helix mutants is lethal to bacterial growth. The lethal amino-acid substitutions occurred at four hydrophobic residues on one face of the flap-tip helix (L901, L902, I905, and F906 of the β subunit of E. coli RNA polymerase;
Thus, the properties of the flap-tip helix make it an ideal candidate for rational design of a drug, e.g., an antibiotic, as any agent that specifically binds to the flap-tip helix should block function of transcription factors essential for bacterial viability and thus those agents will inhibit a wide variety of bacterial RNA polymerases and kill a wide variety of bacteria. Further, because the flap-tip helix interacts with multiple essential transcription factors, it should be relatively difficult for bacteria to acquire natural resistance to antibiotics targeted to the flap-tip helix by mutations that alter the amino-acid sequence of the flap-tip helix. Such mutations would also compromise interactions with the essential transcription factors and thus block their function. Hence, the flap-tip helix is a novel target for design of new antibiotics that is highly likely to yield drugs that will be effective against a wide variety of bacterially caused diseases.
Thus, the invention provides a method to identify one or more agents which inhibit or prevent the binding of a moiety to the flap-tip helix of the β subunit of core RNA polymerase. In one embodiment, the method comprises contacting the one or more agents with isolated core RNA polymerase, or an isolated β subunit of RNA polymerase or a portion thereof which comprises the flap-tip helix, so as to form a complex. As used herein, “isolated and/or purified” refers to in vitro preparation, isolation and/or purification of a peptide, protein or a complex of biomolecules, e.g., core RNA polymerase, so that it is not associated with in vivo substances or is substantially purified from in vitro substances. The portion of the β subunit may include the flap domain, e.g., residues corresponding to residues 830 to 1085, or flap-tip helix, e.g., residues 900 to 907, residues 897 to 907, residues 900 to 909, or residues 886 to 953 of β of E. coli RNA polymerase. Preferably, the portion of the β subunit which includes the flap-tip helix comprises at least 8, more preferably at least 10, and even more preferably at least 20, residues, although smaller fragments are also envisioned. The complex is contacted with a moiety, e.g., an isolated moiety, which specifically binds the flap-tip helix and then it is detected or determined whether the one or more agents inhibit or prevent the binding of the moiety to the flap-tip helix. In another embodiment, the one or more agents is contacted with a moiety, e.g., an isolated moiety, which specifically binds the flap-tip helix so as to form a complex. For example, the moiety may be a transcription factor such as an initiation factor, e.g., σ, an elongation factor, e.g., NusA or NusG, or an anti-termination protein including λ N or Q or rfah proteins, or another subunit of RNA polymerase such as the β′ subunit. For example, the β′ subunit-flap-tip helix interaction may be important for stable transcription elongation complexes. The complex is contacted with isolated core RNA polymerase, or an isolated β subunit of RNA polymerase or a portion thereof which comprises the flap-tip helix. Then it is detected or determined whether the one or more agents inhibit or prevent the binding of the moiety to the flap-tip helix.
The detection or determination of binding or inhibition or prevention thereof can be accomplished by a variety of methods some of which are described herein. For example, core RNA polymerase, the β subunit or a portion thereof may be labeled or may bind to a detectable label such as a labeled antibody. Alternatively, or in addition to, the moiety may be labeled or bind to a detectable label. Thus, assays such as fluorescence resonance energy transfer assays, luminescence resonance energy transfer assays, cleavage assays (protease or nuclease cleavage), crosslinking assays, scintillation proximity assays or fluorescence perturbation assays and the like may be employed.
In another embodiment, the agents may be identified in vivo. For example, the invention also provides a method in which one or more agents is contacted with a recombinant cell. The recombinant cell expresses a first fusion polypeptide and a second fusion polypeptide. The first fusion polypeptide comprises the flap-tip helix and a first polypeptide and the second fusion polypeptide comprises the prokaryotic protein or a fragment thereof which specifically binds the flap-tip helix and a second polypeptide which is a ligand for the first polypeptide. The binding of the first polypeptide and the second polypeptide yields a detectable signal. Then it is detected or determined whether the one or more agents inhibits or prevents the signal. An exemplary method employs a first or the second polypeptide which comprises a DNA binding domain while the other polypeptide comprises an activation domain.
Also provided is one or more agents identified by the methods of the invention. Further provided is a method of using those agents. The method comprises contacting a cell with the agent and detecting or determining whether the agent inhibits or prevents the growth of the cell. Preferably, the agent inhibits or prevents the growth of a prokaryotic cell but not a eukaryotic cell.
The invention also provides a method to identify moieties which specifically bind the flap-tip helix. In one embodiment, a peptide comprising the flap-tip helix, e.g., residues corresponding to residues 886 to 953 of β of E. coli RNA polymerase, or a portion thereof is contacted with the one or more moieties. Then it is determined whether the one or more moieties specifically bind to the flap-tip helix. In one embodiment, the moiety is present in the surface of a recombinant phage, virus, or cell. Thus, a library of molecules expressed by recombinant phage, virus or cells, e.g., bacteria or yeast, is contacted with a peptide comprising the flap-tip helix or a portion thereof and molecules that specifically bind to the peptide identified and optionally isolated.
The invention thus further provides an isolated and purified portion of the β subunit of RNA polymerase which binds to the β′ subunit, NusA and/or σ. Preferably, the portion comprises residues corresponding to 886 to 953, residues 897 to 907, or residues 900 to 909 of the β subunit of E. coli RNA polymerase.
The invention further provides agents identified by the methods of the invention and, in particular, agents which inhibit the growth of prokaryotic cells which are associated with disease, see e.g., Zinsser Microbiology (17th ed., Appleton-Century-Crofts, N.Y. (1980).
Also provided is a method to identify one or more agents which inhibit or prevent transcription from a promoter that is dependent on a −35 sequence for activity. The method comprises contacting the one or more agents with a composition for transcription comprising wild-type RNA polymerase and a first construct comprising a first promoter that is dependent on a −35 sequence to promote transcription and operably linked to an open reading frame for a gene. Then an agent is identified that inhibits or prevents transcription from the first construct relative to transcription by wild-type RNA polymerase from a second construct comprising a second promoter that promotes transcription independent of the presence of a −35 sequence, which second promoter is operably linked to an open reading frame for a gene, thereby identifying an agent that inhibits or prevents transcription from a promoter that is dependent on a −35 sequence for activity. In one embodiment, the one or more agents are contacted with a recombinant cell augmented with the first construct. Preferably, the level of transcription from the first construct in the presence of the agent is substantially the same as the level of transcription by a mutant RNA polymerase comprising a mutant flap-tip helix from a third construct comprising a promoter that is dependent on a −35 sequence to promote transcription and operably linked to an open reading frame for a gene. Also preferably, the agent does not inhibit transcription by a mutant RNA polymerase comprising a mutant flap-tip helix from a third construct comprising a promoter that promotes transcription independent of the presence of a −35 sequence and operably linked to an open reading frame for a gene.
Bacterial RNA polymerase synthesizes RNA from cellular genes and thus plays a central role in the regulation of gene expression. Core RNA polymerase can synthesize RNA but is unable to specifically bind DNA at promoter sites. To specifically bind DNA and initiate transcription of genes, a binds to core to form the holoenzyme. Each step in initiation, elongation and termination are potential sites for inhibitors of transcription.
Gene expression often is regulated during RNA chain elongation. Regulation depends both on interruptions to transcription caused by pause, arrest, and termination signals encoded in the DNA and RNA and on auxiliary proteins that modify the response of RNA polymerase (RNAP) to these signals. Pausing (a temporary delay in chain elongation) synchronizes transcription and translation in prokaryotes, slows RNAP to allow timely interaction of regulatory factors, and is a precursor to both arrest (complete halting without dissociation; Komissarova and Kashler, 1997; Mote and Reines, 1998), and dissociation of the transcription elongation complex (TEC) at ρ-dependent and ρ-independent terminators (Richardson and Greenblatt, 1996).
Numerous auxiliary proteins modulate pausing in organisms from bacteria to humans. Two of these, NusA and NusG, are universally conserved among bacteria and archaebacteria (Ingham et al., 1998) are typically essential to cell viability, and, respectively, inhibit or stimulate pausing by bacterial RNAP (Burns et al., 1999). NusA and NusG also modulate the termination activity of ρ protein (which dissociates paused TECs) and, together with other auxiliary proteins like λ N or Q, assemble antitermination TECs that resist pausing and termination.
Associated with a σ factor, bacterial core RNAP first binds to 40-60 bp, of duplex promoter DNA. In a series of at least three transitions that includes downstream extension of its footprint on DNA and extensive burial of nonpolar surface with significant protein conformational changes, σ-RNAP separates the double helix, placing the template DNA strand into the active site channel (Craig et al., 1998 and references therein). These transitions are orchestrated via specific interactions of σ with the melted nontemplate strand and upstream duplex DNA, and the α subunit C-terminal domain (not visible in the structure) with DNA further upstream. Thus, contacts to DNA in the promoter and initiating complexes span 70-90 bp (235-305 Å versus RNAP's maximal dimension of 150 Å), requiring that DNA wrap around RNAP (Craig et al., 1998 and references therein). The initiating complex can synthesize and release RNAs up to about 10 nt in length apparently without loss of these extensive contact during abortive initiation.
Further transcription requires rearrangement to a highly stable TEC. The TEC must successfully traverse over 104 (in bacteria) to 106 (in eukaryotes) bp without dissociation (RNAPs cannot resume synthesis of RNAs once they are released). In bacteria, this transition is accomplished by breaking contacts of σ to the promoter and to core RNAP, threading RNA into an exit tunnel, and rearranging DNA contacts so that the footprint is reduced to only about 35 bp (−17 to +18). Formation of a eukaryotic TEC additionally required multiple phosphorylation of a heptapeptide repeat at the C terminus of its largest subunit by specific kinases. This phosphorylation is key to an activating transition in which association of special factors equip RNAPII for long-distance transcription on a chromatin template (see Uptain et al., 1997; Shilatifard, 1998 and references therein).
To terminate transcription, the stability of the TEC must decrease. In bacteria, this can be accomplished by an intrinsic termination signal consisting of a G+C-rich RNA hairpin followed by 7-9 nt of U-rich RNA. In eukaryotes, the mechanism of termination is unknown, but appears to require loss of some factors and possibly the action of others that dissociate the complex (see Uptain et al., 1997).
The new Taq RNAP and yRNAPII structures confirm the basic RNAP architecture inferred from the earlier EM results and reveal important features not previously resolved. Both core RNAPs contain the “jaws” previously seen open or closed in different structures (plus and minus a for E. coli RNAP; in different crystal forms of core yRNAPII). The increased resolution of the new structures reveals that the jaws actually consist of an upper hinged arm and a broader underlying shelf. In the Taq RNAP structure, this hinged arm (β domain 2) appears open, even though σ appears absent. In both yRNAPII structures the arm is closed.
Zhang et al. (1999) definitively located the active site in a deep pocket at the junction of the jaws, the same location inferred from the yRNAPII TEC structure by Poglitsch et al. (1999). What was previously thought to be a continuous 25 Å channel extending from the jaws through the main body of the enzyme (through which duplex DNA or RNA-DNA duplex could pass) is actually blocked within the jaws of both RNAPs by significant protein density (comprised of β′ regions F and G in Taq RNAP, Zhang et al., 1999; see also
Both groups also propose a similar path for the nascent RNA-template DNA hybrid within the active site channel, which in Taq RNAP routes the RNA through a pocket in β that binds rifampicin (an inhibitor that blocks initiation by bacterial RNAP). Separation of the RNA:DNA hybrid would occur near a feature called the “rudder” in Taq RNAP, which is not resolved or not present in the yRNAPII structure. After separation, the RNA transcript is thought to exit RNAP in a tunnel; both the bacterial and eukaryotic structures contain a putative RNA exit tunnel composed of a groove covered by a mobile domain. In Taq RNAP, the flap-like domain (β domain 6) connects to the body of the enzyme via a hinge-like stem and could close over the exiting RNA from above the tunnel. In yRNAPII, an apparently larger hinged domain reaches over the RNA exit tunnel from below. The yRNAPII hinged domain is significantly displaced away from the exit tunnel by crystal packing forces in the X-ray structure (relative to its position in the TEC EM structure), confirming that this domain is mobile (see
Previous biochemical studies indicate that or may contact the core enzyme in three locations whose movement relative to one another could open and close RNAP's active site channel, which encloses the RNA:DNA hybrid, and RNA exit tunnel, which encloses the exiting RNA. On contact is to the very tip of the flap domain (Fisher and Blumenthal, 1980; Borukhov et al., 1991). As described above and by Zhang et al. (1999), the flap (β domain 6) might open and close over the exiting RNA. The other two contacts are to parts of RNAP that could close the active site channel: the prominent coiled-coil in β′ that projects from the rudder on the lower surface of the active site channel (Arthur and Burgess, 1998), and two helices (β domain 3) that cap the active site channel in the Taq RNAP structure (Owens et al., 1998). If RNAP assumed a closed conformation, these two pairs of α helices could approach each other at the upstream edge of the active site channel, conceivably stabilizing the position of the rudder and locking the channel in the closed conformation.
It is striking that the active site channel in the Taq RNAP structure is more open than needed to fit an 8 bp RNA:DNA hybrid. The ability of major domains of RNAP to move is directly confirmed by the structures in which jaws are opened or closed and by demonstration that the hinged domain of RNAPII moves away from the RNA exit tunnel (Fu et al., 1999). Thus, it appears possible that the jaws, the active site channel, and the RNA exit tunnel all may be able to open and close semi-independently.
This leads to the obvious possibility that σ contacts to the flap, the β′ coiled-coil, and β domain 3 hold open the active site channel and RNA exit tunnel (in a conformation similar to the Taq RNAP crystal structure), that release of σ from these contacts allows these two parts of RNAP to close, and that this closure explains the change from unstable initiating complexes to the stable TEC. In particular, a complementary or induced fit between the inner surface of the active site channel and the RNA:DNA hybrid is an appealing explanation for the major energy of stabilization in the TEC.
Such a model explains several properties, of promoter complexes and TECs. In the σ-RNAP complex, the opening of the active site channel would allow the entry of promoter DNA, possibly triggering closure of the jaws on the downstream DNA. Anchoring the DNA between RNAP's downstream contact and σ bound at the upstream face of RNAP could facilitate DNA strand separation by σ to form the transcription bubble. At this point, σ would continue to hold open the active site channel and RNA exit tunnel. When the RNA transcript grows to ˜8 nt, it will have filled the rifampicin-binding site in β, its 5′ end will reach the transcript separation point or rudder (see Zhang et al., 1999), and the growing RNA chain would encounter σ bound to β domain 3 and the β′ coiled-coil. Further chain extension could require loss of these contacts and in the process allow the growing chain to pass under the flap as the RNA separates from the DNA template. Coincident or subsequent loss of the σ-to-flap contact would then allow the flap to close over the RNA exit tunnel, configuring RNAP for processive RNA synthesis.
A requirement to release a in order to stably enclose the RNA:DNA hybrid within the active site channel and the exiting RNA under the flap would explain why σ and RNA compete for binding to RNAP-DNA complexes (Daube and von Hippel, 1999) and why 8-9 nt RNAs are not stably in TECs when a has been released (Chamberlin and Hsu, 1996; Korzheva et al., 1998 and references therein). Although the free energy of base pairing in the RNA:DNA hybrid (as well as the interaction of RNAP's jaws with downstream DNA) probably makes a contribution to TEC stability (see Nudler, 1999 and references therein), these interactions alone do not appear sufficient since both already exist in initiating complexes without conferring TEC-like stability. An additional energetic contribution made by locking a complementary protein surface tightly around the helical shape of the RNA:DNA hybrid best explains the TEC's stability (Korzheva et al., 1998).
A terminator hairpin might destabilize the TEC by reopening the RNA exit tunnel and active site channel of RNAP. In principle, wedging of the terminator hairpin under the flap domain could open the RNA exit tunnel; disruption of even 1 bp in the RNA:DNA hybrid could be sufficient to open the active site channel if maintenance of its closed conformation depends on a precise fit of the channel around the hybrid. In this view, termination would involve the reversal of structural transitions observed during initiation. This model is similar to that proposed for the single-subunit T7 RNAP, where both TEC formation and termination appear to involve movement of a loop in the N-terminal domain that contacts RNA (Lyakhov et al., 1997).
The idea that TEC destabilization at intrinsic terminators depends in part on wedging open the flexible flap that covers the RNA exit runnel is consistent with the position of cross-linking to RNAP of a nascent RNA hairpin that is part of a transcriptional pause signal closely related to intrinsic termination signals (Wang et al., 1997 and references therein). In TECs halted at this pause, the loop of the pause hairpin cross-links specifically to amino acid residues located at the tip of the flap domain (β domain 6) in the Taq RNAP structure (Wang et al., 1997). Thus, the pause hairpin-appears to form between the flap and the body of the enzyme (partially within the RNA exit tunnel). So positioned, it could alter the active site channel's conformation, affect the position of the RNA:DNA hybrid, or both. This would explain how the hairpin inhibits proper alignment of the of the 3′ OH with the active site. At a terminator, the hairpin forms even closer to the RNA 3′ end (7-9 nt away versus 11 nt for the pause; see Chan et al., 1997 and references therein), and could wedge open the RNA exit tunnel setting up release of the transcript.
The idea that termination requires opening of the active site channel is supported by the observations of TEC dissociation when a hairpin or antisense oligonucleotide pairs close enough to the RNA 3′ end to affect hybrid structure (position −8 or −9, see Artsimovitch and Landick, 1998; Korzheva et al., 1998; Yarnell and Roberts, 1999; Nudler, 1999 and references therein). This upstream edge of the hybrid may be directly adjacent to contacts that lock the channel closed, so that a disruption of base-pairing would open the channel. Thus, a terminator hairpin might return RNA polymerase to a conformation similar to that of the promoter complex, first by forming under the flap and opening the RNA exit tunnel, and then by melting the −8 bp in the hybrid and disrupting the closed conformation of the active site channel. Coupled with weak rU dA base-pairing in the remaining hybrid and absence of σ (which maintains the transcription bubble in a promoter complex), these events could lead to rapid collapse of the bubble and TEC dissociation (Artsimovitch and Landick, 1998; Korzheva et al., 1998; Nudler, 1999 and references therein). Thus the new structure of RNAP is consistent with the idea that termination could occur by an opening of RNAP followed by transcription bubble collapse. However, an alternative model in which hairpin formation pulls the RNA out of the enzyme without disrupting RNAP's structure remains equally viable (see Yarnell and Roberts, 1999).
The invention will be further described by the following non-limiting examples.
EXAMPLE 1 Allosteric Control of RNA PolymeraseMaterials and Methods
Crosslinking of the Pause Hairpin to RNA Polymerase
To confirm the assignment of βF906 as the crosslinking target of 5-iodoU in the pause hairpin loop, two types of experiments were performed. First, paused TECs containing either wild-type or βK909C mutant RNAPs and a wild-type pause hairpin loop derivatized with 5-iodoU and [α-32P]CMP were prepared (
The coordinates of the tetraloop pause hairpin were assembled from coordinates of a canonical A-form RNA stem and a C-UUCG-G tetraloop determined by NMR by Colemenjaro and Tinoco (1999), which is essentially identical to the C-UUCG-G tetraloop crystal structure recently reported by Ennifar et al. (Ennifar et al., 2000). The hairpin was modeled into a TEC structural model (Korzheva et al., 2000, coordinates kindly supplied by S. Darst) that was based on the crystal structure of Thermus aquaticus RNAP (Zhang et al., 1999). The hairpin was aligned with the TEC structure (see
To map-1-nt crosslinks in RNA polymerase, the partial chemical cleavage strategy of Grachev et al. (1989) was employed. Paused TECs were prepared as described previously (Wang et al., 1997), except that 4-thioU was incorporated at the −11 position rather than in the pause hairpin loop, using a mutant template that specified U at −11. A portion of the paused TECs was converted to rapidly elongating TECs by incubation with an antisense oligonucleotide that pairs to bases −33 to −15 relative to the pause RNA 3′ end. After UV irradiation at 365 nm to allow crosslinking, crosslinked β and β¢ subunits were separated in SDS polyacrylamide gels (8-16% gradient), the fragments isolated, and partial CNBr digestion performed. The partially cleaved products were separated on a second SDS polyacryalmide gel and compared to the products of control digestions of β or β¢ that had been radioactively labeled at their C- or N-termini, respectively, via heart-muscle-kinase (HMK)-sequence tags and reaction with HMK and [γ32P]ATP (
To assess the contribution of the flap-tip helix to pausing and to NusA regulation of transcription, halted TECs containing wild-type or βD(900-9009) RNAP were prepared from synthetic oligonucleotides using the procedure of Siderenkov et al. (1998) (
(Artismovitch et al., 2000). 100 nM template strand and RNA (UUUUUACAGCCAUC; SEQ ID NO:2) were annealed in 20 mM Tris-HCl, pH 7.9, 20 mM NaCl, 0.1 mM EDTA, and then incubated with 100 nM RNAP in the same buffer plus 5% glycerol, 5 mM MgC12, 0.1 mM DTT, 50 μg BSA/ml for 10 minutes at 22° C. After incubation at 37° C. with nontemplate DNA (250 nM) for 10 minutes and then with 2.5 μM each ATP and GTP and 1 μM [a-32P]CTP for 10 minutes to form C24 TECs, NTPs were adjusted to 10 μM GTP, 150 μM each ATP, UTP, and CTP, and pausing was assayed with or without NusA as described previously (
To test the rigid-body versus allosteric models, a pause hairpin was studied that inhibits nucleotide addition by a factor of 10 to 20 at the Escherichia coli his pause site. The his pause synchronizes transcription with translation in the attenuation control region of the E. coli his operon (Chan and Landick, 1993). The pause signal is multipartite; interactions of downstream DNA, 3′-proximal RNA, and NTP substrate, together with the pause hairpin, inhibit nucleotide addition by a factor of about 100 (Chan and Landick, 1993). The pause hairpin loop substituted with 5-iodoU photocrosslinks strongly to RNA polymerase's β-subunit flap domain between residues 903 and 952, causing an unusual retardation of β during SDS-PAGE relative to RNA-β crosslinks in nonpaused TECs (Wang et al., 2000). This crosslink also occurs with a 5-iodoU-substituted tetraloop pause hairpin (
F906 is the likely target of hairpin-loop crosslinking because the strong, shifted-β band disappeared when a βF906A, but not a βF934A, mutant RNAP was used (
F906 is located in a short c-helix at the tip of RNA polymerase's flap domain (Zhang et al., 1999). The flap is flexibly connected to RNA polymerase, held open by lattice forces in a crystal structure, and thought to close over the exiting RNA in a TEC (Zhang et al., 199; Korzheva et al., 2000; Finn et al., 2000), probably by contact of a hydrophobic patch on the flap-tip helix to the main body of RNA polymerase (
To distinguish these possibilities, three predictions of the rigid-body model were tested: (i) hairpin formation should move the −11 nt; (ii) lengthening the 3-nt spacer between the hairpin and hybrid should reduce the hairpin's ability to pull RNA away from the active site and thus to stimulate pausing; and (iii) stabilizing the hairpin by lengthening its stem should increase its stimulation of pausing.
To map its contacts to RNA polymerase, the −11 nt was substituted with 4-thioU (5-iodoU crosslinked poorly at −11). Separately, the 3′-terminal nt was substituted with 5-iodoU. Photocrosslinking was performed in the paused TEC, or after hybridization of an antisense oligonucleotide that converts it to a rapidly elongating TEC (
To test effects of spacer length, spacer length was varied from 2 nt to 5 nt (
To test lengthening the hairpin stem, the stem was changed from 5 to 8 bp (using the optimal 4-nt spacer). Hairpin-dependent pausing was lost without NusA, again contradicting the rigid-body model (
Together, these results and previous findings make a convincing case against the rigid-body model: (i) the pause hairpin cannot be imitated by antisense oligonucleotide-pairing to nascent-RNA (Artsimovitch and Landick, 1998); (ii) unraveling of the RNA:DNA hybrid, required if hairpin formation pulls RNA through the exit channel, does not occur in a paused TEC (Lee and Landick, 1992); (iii) the hairpin creates steric clash with RNA polymerase, as required by the rigid-body model, only if the flap closes in the TEC (
Because NusA enhancement of pausing requires the pause hairpin (Chan and Landick, 1993; Artsimovitch and Landick, 2000), made suboptimal pause signals work better (
To test whether the flap-tip helix was required for pausing and NusA action, a RNA polymerase lacking the helix (βΔ(900-909)) was prepared and tested. In the absence of NusA, the helix deletion reduced hairpin stimulation of pausing from about 10-fold to about 2-fold (
Therefore, NusA likely stabilizes pause hairpin-flap interaction, which, by opening the RNA exit channel, may allosterically affect RNA polymerase's active site. Interaction of the composite NusA-β-subunit surface with RNA may stabilize RNA structures and explain NusA's ability to accelerate cotranscriptional folding of RNA (Pan et al., 1999).
How might an allosteric signal generated by flap contact affect catalysis in the active site, which is 65 Å from the flap-tip helix? The flap domain connects to RNA polymerase through a two-stranded, antiparallel beta-sheet (the connector). The connector runs along the active-site cleft to highly conserved amino acids in the active site (E813, D814, and K1065;
Definition of the flap-tip helix as an allosteric site on RNA polymerase provides a new framework for understanding RNAP's regulation. σ also binds RNA polymerase's flap (Gruber, T. I. Artsimovitch, K Geszvain, R. Landick and C. Gross, unpublished data); a may open the RNA exit channel to thread RNA into the channel: σ release may allow the channel to close for efficient transcript elongation (Mooney and Landick, 1999). Like pause hairpins, terminator hairpins probably also open the RNA exit channel, rather than pull RNA out of RNA polymerase, and then dissociate the TEC by invading the RNA:DNA hybrid, opening the active-site cleft, and triggering collapse of the transcription bubble (Korzheva et al., 2000; Artsimovitch and Landick, 2000). Finally, eukaryotic RNA polymerases also contain a flap domain, making the flap an attractive target for both prokaryotic and eukaryotic regulators of transcription.
EXAMPLE 2 Flap Domain InteractionsAmino acid substitutions in the flap-tip helix (Example 1) can prevent bacterial growth. To determine whether bacterial growth is dependent on the hydrophobicity of the flap-tip helix or a particular amino acid sequence, constructs were prepared with various substitutions in the flap-tip domain. The substitutions were in a hydrophobic patch on the flap-tip helix (
A simple assay was employed to test the effect of flap-tip helix substitutions on bacterial growth. Cells were transfected with a plasmid, such as pRL702 (
Table 1 shows the relative plating efficiencies of bacteria carrying plasmids that encode β subunits with substitutions in the flap-tip helix. The data show that the specific amino acids present in the hydrophobic patch are not important to bacterial growth. Rather, the nonpolar nature of the patch is important. For instance, substitution of leucine 901, a central residue in the hydrophobic patch, with alanine has a much lesser effect than substitution of leucine 901 with polar amino acids (lysine, arginine or glutamine). A deletion of the flap-tip helix (Δ(900-909)) is as lethal as the polar substitutions at 901, showing that these substitutions likely disrupt some essential activity of the flap-tip helix, rather than result in a toxic effect. Most substitutions at positions 902, 905, and 906 are less toxic than similar substitutions at 901, but the overall pattern of these effects indicates that the hydrophobic patch makes a hydrophobic interaction with some other molecule, e.g., part of RNAP, that is quite significant for proper function of the enzyme.
To understand which aspect of RNAP function was compromised by the flap-tip substitutions, the properties of the lethal deletion mutant, βΔ(900-909), were studied. Synthesis of the α, β, and β′ subunits of RNAP were controlled by a T7 RNAP promoter on a plasmid that encodes all three subunits (derivatives of pIA312;
Purified RNAPs were then used for in vitro transcription reactions. The βΔ(900-909) mutant RNAP was found to be competent for elongation of transcripts and for termination of transcription (Toulokhonov et al., 2001). For instance, βΔ(900-909) mutant RNAP was as active on a poly(dA dT) template as wild-type RNAP (assayed as described in Gross et al., 1976), but the mutant was incapable of initiation from a strong E. coli RNAP promoter, the T7 A1 promoter (
The βΔ(900-909) mutant RNAP displayed a defect in the stimulation of poly(dA dT) by σ70, which ordinarily increases poly(dA dT) by a factor of 2-3. Fisher and Blumenthal (1980) showed that trypsin cleavage of the β subunit was protected by σ70. This trypsin cleavage site was subsequently mapped to R903 and K909 (Borukhov et al., 1991), residues in or directly adjacent to the flap-tip helix. Thus, the defect in transcription initiation by βΔ(900-909) RNAP on the T7 A1 promoter may reflect some defect in the way RNAP interacts with σ factors.
To dissect the basis of the transcriptional defect of the flap-tip helix mutants, transcription from a T7 A1 promoter DNA template was compared to transcription from a similar template that contained a so-called consensus galP1 promoter, which does not require interaction of σ70 with the −35 promoter element (Kumar et al., 1994; Severinova et al., 1998). These transcription templates were produced from the plasmid pIA171 (Artsimovitch et al., 2000) by PCR with oligonucleotides that yielded, either the wild-type T7 A1 promoter of a galP1 consensus −10 derivative with the sequence shown in
These results strongly support the hypothesis that the flap-tip helix must interact with region 4 of σ factors to facilitate transcriptional initiation at promoters that require σ factor contact to the −35 promoter element.
Flap-Tie Helix Contacts with Region 4.2 of σ70
To test directly whether the flap-tip helix contacts region 4 of σ factors, the ability of trypsin to cleave the flap-tip in RNAPs either in the absence of σ factors or in the presence or wild-type a or a lacking region 1 or region 4 was tested (
To test for the effect of the flap-tip helix hydrophobic patch on the ability of σ70 to protect the β subunit against trypsin cleavage, the rates of trypsin cleavage of wild-type RNAP to an RNAP bearing the LQ901 substitution were compared (Table 3). The LQ901 substitution was chosen because position 901 exhibited the strongest effects of flap-tip substitutions and because the L to Q change does not create a trypsin cleavage site (trypsin cleaves after lysine and arginine residues). From the results, it was concluded that the flap-tip hydrophobic patch is important in allowing σ factor interaction in a way that protects the β subunit against trypsin cleavage.
To test which region of or σ70 interacts with the flap-tip helix, the effect of removing parts of σ70 on its ability to protect the flap-tip against trypsin cleavage was examined. Removal of region 4 of σ, the portion known to interact with the −35 promoter sequence (Siegele et al., 1989; Gordella et al., 1989; Pombroski et al., 1992), caused a complete loss of σ's ability to protect against trypsin cleavage, whereas removal of region 1 of σ caused a slight increase in the rate of cleavage (Table 3).
Flap-Tip Helix Contacts with NusA
RNAP with a deletion of the flap-tip helix (Δ(900-909)) is completely resistant to the action of NusA protein (Toulokhonov et al., 2001). Further, part of NusA is positioned near the flap-tip in paused transcription complexes (Toulokhonov et al., 2001), making it likely that NusA interacts with the flap-tip helix. Using a trypsin cleavage assay, it was found that NusA protects the flap-tip helix from trypsin cleavage (
From the results described hereinabove, both σ70 and NusA make contacts to the flap-tip helix that are important to their functions. At least for σ70, this interaction requires principally a hydrophobic patch in the flap-tip helix, rather than a particular amino acid sequence at the flap-tip. Since the interactions of both σ70 and NusA with the flap-tip are important for bacterial viability, the flap-tip helix is an excellent target for isolation or design of antibacterial compounds. Compounds that bind the flap-tip helix should block the function of transcription factors essential for bacterial viability and thus kill bacteria. Moreover, the flap-tip helix is a small target for design of inhibitors and is highly conserved among bacteria. Therefore, it should be relatively easy to obtain antibiotics from any compound that binds to the flap-tip helix, antibiotics which are likely effective against a wide variety of bacteria. Because the flap-tip helix is required for interactions with multiple transcription factors (e.g., σ initiation factors and NusA), it should be relatively difficult for bacteria to acquire natural resistance to antibiotics targeted to the flap-tip helix by mutations that alter the amino acid sequence of the flap-tip helix. Such mutations would also compromise interactions with the essential transcription factors and thus block their function.
EXAMPLE 3 Methods To Identity Inhibitors of Flap-Tip Helix InteractionsThere are three likely interacting partners of the flap-tip helix of Escherichia coli RNA polymerase: the σ70 initiation factor, the NusA transcription elongation factor, and nascent RNA secondary structures. As described above, both σ70 and NusA are unable to function when the flap-tip helix is deleted. Therefore, inhibitors of these interactions block transcription initiation in E. coli and, because the flap-tip helix is conserved among bacteria, but not eukaryotes, it is likely that such inhibitors function as broad-spectrum antibiotics with specificity for bacterial and not human or animal cells. It also is likely that other transcription factors, such as alternative a factors also require the flap-tip helix for function. The exemplary assays described below can be used to detect interactions of transcription factors with the flap-tip helix and to screen for inhibitors of these interactions that would serve as lead compounds for antibiotic design. The same assays can be adapted to characterize interactions of transcription factors other than σ70 and NusA and to look for specific inhibitors of those interactions.
There are three classes of assays that can be performed. In the first, the flap-tip helix is left intact in RNA polymerase and its interactions are monitored by one of several methods described below. In the second, the flap-tip helix or the entire flap domain is displayed separately from RNA polymerase and the interactions of proteins like σ70 or NusA are assayed by methods that detect simple binding. In this second case, because only the flap domain or flap-tip helix is presented as a binding target, it is not necessary to distinguish interactions of the flap-tip helix from interactions with other parts of RNA polymerase. In the third class of assay, the flap-tip helix or the entire flap domain is displayed separately from RNA polymerase and used to look directly for molecules that bind the flap-tip helix. Because bulky molecules that bind the flap-tip helix are likely to block σ70 or NusA function, such molecules are good candidates for lead compounds in antibiotic design.
I. Alterations of RNA polymerase. NusA, and σ70 to Facilitate Interaction Assays
The assays can take advantage existing or easily constructed mutants in the flap-tip helix, σ70, and NusA as controls to distinguish interactions of the flap-tip helix from interactions with other parts of RNA polymerase. Mutants in the flap-tip helix were constructed using a plasmid, pRL702, that expresses the β subunit of RNA polymerase carrying a hexahistidine tag and hemagglutinin epitope at its N-terminus. This plasmid is similar to pRW308 (Weilbaecher et al., 1994), except that pRW308 expresses a wild-type version of the β′ subunit of E. coli RNA polymerase. A deletion of the flap-tip helix, β(Δ900-909), and point mutants LR901, LQ901, LP902, and IQ905, that are unable to function with σ70, were prepared. The deletion β(Δ900-909) is unable to function with NusA. As described below, LQ901 directly blocks interaction of σ70 with the flap-tip helix. These mutants of the flap-tip helix, either in intact RNA polymerase, or in polypeptides expressing just the β subunit, the flap domain, or the flap-tip helix serves as powerful controls to identify molecules that interact specifically with the flap-tip helix.
In addition to its interaction with the flap-tip helix, σ70 is known to bind tightly to a coiled-coil domain in the β′ subunit of RNA polymerase through so-called region 2 of σ70 (Arthur et al., 2000; Burgess et al., 1998; Arthur and Burgess, 1998). This is the strongest interaction of σ70 with RNA polymerase. This interaction can be prevented from interfering with a flap-tip helix binding assay, either by deleting or mutating region 2 of σ70 or by deleting or mutating the coiled-coil in β′.
Likewise, NusA is known to interact with the C-terminal domain of the α subunit of RNA polymerase through NusA's C-terminal domain (Mah et al., 2000). This is the strongest interaction of NusA with RNA polymerase, but actually is dispensable for its activity in vivo if NusA is produced in cells at higher concentration (Schauer et al., 1987). This interaction of NusA is prevented from interfering with a flap-tip helix binding assay either by deleting or mutating the C-terminal domain of NusA or the C-terminal domain of the α subunit of RNA polymerase.
Desired mutants in RNA polymerase, σ70, or NusA can be prepared using the standard methodology of oligonucleotide-directed mutagenesis of plasmid DNA (Sugimoto et al., 1989).
II. Class 1 AssaysA. Trypsin Cleavage Protection
One of the simplest ways to assay for interaction of a macromolecule with the flap-tip helix is protection against trypsin cleavage. At low concentration, trypsin cleaves RNA polymerase in only three locations, two of which, R903 and K909, are in or near the flap-tip helix Borukhov et al., 1991). Cleavage of R903 or K909 is readily detected by separation of RNA polymerase subunits on an SDS-polyacrylamide gel, whereupon trypsin cleavage of R903 or K909 generates two new bands corresponding to the larger N-terminal portion of the β subunit and the smaller C-terminal portion of the β subunit. Addition of either σ70 or NusA protects the flap-tip helix against trypsin cleavage (Fisher et al., 1980; unpublished observations). Further this is specific to the biologically relevant interaction of the flap-tip helix because σ70 no longer protects the flap-tip helix of a mutant RNA polymerase (L901Q) that is compromised for σ70 function and σ70 interaction with the flap-tip helix (unpublished observations).
This assay is mostly useful to confirm suspected interactions or inhibitors of interaction. Large molecules suspected of interacting with the flap-tip helix may afford protection against trypsin cleavage and could by this inhibition of trypsin cleavage. Smaller molecules that inhibit interaction of σ70 or NusA with the flap-tip helix could prevent σ70 or NusA from inhibiting trypsin cleavage of the flap-tip helix. Therefore small molecule inhibitors of σ70 or NusA interactions with the flap-tip helix could be detected by the loss of σ70 or NusA protection of the flap-tip helix against trypsin cleavage.
B. Fluorescence Resonance Energy Transfer (FRET)
Interactions with the flap-tip helix could be assayed by FRET if the donor or acceptor fluorophore were located near the flap-tip helix and the other partner were located on σ or NusA. When interaction occurs fluorescence energy would be transferred between the two fluorophores owning to their proximity. If the interaction were lost, the FRET signal would decrease. This assay would be adaptable to mass screening for inhibitors of interactions of the flap-tip helix with σ or NusA (Matsumoto et al., 2000). Any compound that inhibited such an interaction would decrease FRET signal and this decrease could be detected in fluorescence instruments that are designed for mass screening. Many methods exist for specific attachment of fluorophores and these can be adapted to locate fluorophores on σ70 or NusA (see, for example, Callaci et al., 1999). Specific attachment of fluorophores or other probes to the flap-tip helix is described below.
C. Fluorescence Perturbation Assay
Interaction of σ70 or NusA with the flap-tip helix also could perturb the fluorescence signal from a fluorophore attached to or near the flap-tip helix, even if the σ70 or NusA did not itself contain a fluorophore. The interaction itself could either increase or decrease the fluorescence of a fluorophore attached to the flap-tip helix by changing the microenvironment around the fluorophore. This assay also would be amenable to mass screening. Any compound that interfered with interaction of σ70 or NusA with the flap-tip helix could eliminate the increase or decrease in fluorescence caused by this interaction and be detected in spectrofluorometers designed for high-throughput assays.
D. Crosslinking Assays
Crosslinking moieties attached to the flap-tip helix can be used to detect molecules that interact with the flap-tip helix by transfer of radioactive or chemical tags to the interacting molecule (see, e.g., Chen et al., 1994 for an example of this method). Thus, molecules that inhibit flap-tip helix interactions could be detected by interference with crosslinking between a suitable reagent attached to the flap-tip helix and a target protein.
E. Tethered Protease or Nuclease Assays
Chemical or enzymatic proteases or nucleases that are attached to the flap-tip helix could be used to detect molecules that interact with the flap-tip helix by cleavage or degradation of the interacting molecules. An example of this methodology is described in Owens et al. (1998). Thus, molecules that inhibit flap-tip helix interactions could be detected by interference with cleavage or degradation of a target protein by a suitable reagent attached to the flap-tip helix.
F. Attachment of Chemical Moieties to the Flap-Tip Helix (“derivatives”)
Some of the assays described above depend on specific attachment of chemical moieties to the flap-tip helix. A general method for this attachment is as follows. A derivative of the β subunit of E. coli RNA polymerase was prepared that contains a cysteine residue in place of the normal lysine residue at position 909 adjacent to the flap-tip helix. These mutant β subunits are expressed from the plasmid pRL702. Additional cysteine substitutions in the β subunit can be prepared using pRL702 by oligonucleotide-directed mutagenesis. The cysteine residue(s) can be reacted with a large variety of commercially available fluorophore or other chemical compounds that react with the free sulfhydryl group (see, for example, Callaci et al., 1998 and Owens et al., 1998). To conduct the attachment reaction under conditions where the desired cysteine is the only one available for reaction, RNA polymerase is reconstituted from individual subunits and split subunits, one of which a fragment of the β subunit on which the desired cysteine residue is the only cysteine residue. Functional RNAP can be reconstituted from α, β′, β(1-643), and β(643-1342) subunits or subunit fragments (Severinov et al., 1995). β(643-1342) contains the entire flap domain, but only three Cys residues (at position 764, 770, and 838). These residues were changed to serine, isoleucine, and serine, respectively, in intact β subunit and were found to support growth of E. coli. Therefore, sulfhydryl-reactive compounds can be reacted with a β(643-1342) fragment in which the tlineonly cysteine residue is present in or near the flap-tip helix, such as the cysteine at 909. Then these derivatized β subunit fragments are used to reconstitute RNA polymerase in vitro for use in the assays described above.
III. Class 2 AssaysA. Localization Assays
In localization assays, the two interacting partner proteins are assayed with one protein partner immobilized on a solid support and the second partner protein tagged in some way to reveal its interaction with the immobilized protein. There are a large number of variations to localization assays, all of which are applicable to assaying interactions of the flap-tip helix. Either the flap-tip helix containing protein or the interacting protein (here NusA or σ70) can serve as the immobilized protein or the marked protein that interacts from solution. In the simplest implementation of these assays, either the flap domain (consisting of E. coli β subunit residues from about 830 to about 1058), of the flap tip helix alone (consisting of at least E. coli β subunit residues 897-907) is attached to the solid support. For instance, the flap-tip helix protein could be attached to the wells of a multiple well plastic plate, either by direct absorption, chemical reaction with derivatized plate wells, binding to another molecule (such as an antibody) attached to the plate wells, or derivatization of the flap-tip helix protein so that it can be attached specifically or non-specifically to the plate well. Binding of the σ70 or NusA protein to the immobilized flap-tip helix protein can be detected in many way, some of which are (i) using a radioactively, fluorescently, luminescently, or phosphorescently labeled σ70 or NusA protein or a σ70 or NusA-protein derivative and detecting binding by the presence of radioactivity, fluorescence, luminescence, or phosphorescence in the plate welts after they are exposed to the σ70 or NusA protein and then washed; (ii) using a radioactively, fluorescently, luminescently, or phosphorescently labeled antibody to σ70 or NusA protein or a σ70- or NusA-protein derivative and detecting binding by the presence of radioactivity, fluorescence, luminescence, or phosphorescence in the plate wells after they are exposed to the σ70 or NusA protein, washed, then exposed to the antibody, and then washed again; (iii) using a fluorescently, luminescendy, or phosphorescently labeled σ70 or NusA protein or a σ70- or NusA-protein derivative and a fluorescently, luminescently, or phosphorescently labeled σ70 or NusA protein or a σ70- or NusA-protein derivative, and then detecting binding by the transfer of energy between one of the molecules that is excited with specific wavelength electromagnetic radiation and the second, which is not excited but whose emissions are monitored (a fluorescence resonance energy transfer, FRET, or luminescence resonance energy transfer, LRET, assay); (iv) using a change in fluorescence polarization when a fluorescently labeled protein interacts with the second protein that is derivatized in such a way as to make it significantly larger than the fluorescently labeled protein (a fluorescence anisotropy assay; see, e.g., Owicki, 2000); and (v) attaching one of the proteins to a solid support containing a scintillant, and then detecting the binding of the other protein, which is radioactively labeled, by activation of the scintillant by the proximity of the radioactive emissions created by the binding reaction (a scintillation proximity assay, SPA, see Cook et al., 1992).
Using localization assays such as those described in this section or variants of these assays, it is possible to screen for compounds that disrupt interactions of σ70 or NusA with the flap-tip helix by adding compounds or mixtures of compounds to the bound proteins or during the binding reaction, and then identifying those compounds that prevent generation of the signal that indicates binding. These assays are adaptable to high-throughput screening and could be used to screen large libraries of candidate inhibitor compounds.
B. In Vivo Assays of Protein Interactions
A second method to identify interactions of the flap-tip helix with σ70 or NusA is to detect the interactions in vivo by a biological signal generated upon interaction of the two proteins. A well-characterized example is the yeast two-hybrid assay (Fields and Sternglanz, 1994). In this case σ70 or NusA protein or a σ70- or NusA-protein derivative is attached to either a DNA-binding domain or an activation domain and the flap-tip helix protein attached to the other domain. If interaction occurs, recruitment of the activation domain to the DNA binding domain, which is localized near a promoter in living cells, activates transcription of a reporter gene, which in turn generates a visible signal, such as changing the color of colonies of the organism growing on a suitable solid support. This assay also is adaptable to high-throughput screening. Cells that generate the positive signal upon interaction of σ70 or NusA with the flap-tip helix protein are placed in the wells of a multiple well plastic plate together with candidate inhibitors of the interaction or mixtures of inhibitors, and then the presence or absence of interaction is detected by automated plate readers.
An in vivo assay based on a −35 promoter sequence can also be used. For example, one cell expresses a construct with a −35 promoter sequence linked to one marker gene and another cell expresses a construct with a −10 promoter sequence linked to the same marker gene. Alternatively, one cell expresses a construct with a −35 promoter sequence linked to one marker gene and a construct with a −10 promoter sequence linked to a different marker gene. Agents which inhibit the expression from the −35 promoter construct in cells expressing wild-type β, e.g., inhibition at a level similar to that from the −35 promoter construct in cells expressing β with a mutation in the flap-tip helix in the absence of the agent, and not from the −10 promoter construct are candidate inhibitors of the flap-tip helix. In vitro transcription reactions which measure the amount or level of the transcription product from the −35 or −10 promoter sequences may also be employed.
IV. Class 3 Assays (Direct Detection of Molecules that Bind the Flap-Tip Helix)
In this class of assay, compounds that bind the flap-tip helix are identified directly and then subsequently tested for their ability to interfere with NusA or σ70 function using in vitro transcription assays. In these assays the derivatives of the flap-tip helix that fail to bind σ70 or NusA, such as the β(Δ900-909) deletion can be used as a counter screen to eliminate compounds that do not bind specifically to the flap-tip helix.
A. Localization Assays
The same methods described above for localization assays can be used to look for molecules that interact with the flap-tip helix by attaching the candidate compounds to a solid support and then using a derivative of the flap-tip helix that can be detected upon binding. Alternatively, the flap-tip helix can be attached to a solid support and the interacting compounds can be detected provided that candidate compounds are derivatized in a manner that allows their detection upon binding to the solid support.
B. Yeast Two-Hybrid Assay
The flap-tip helix can be attached to either the DNA binding domain of the activator domain in a yeast-two-hybrid assay σ70 or NusA protein or a σ70- or NusA-protein derivative (Fields and Sternglanz, 1994). Libraries of compounds attached to the other partner in the yeast two-hybrid assay can then be screened to identify interacting compounds.
C. Phage or Cell Display Assay
In the phage- or cell-display assay (Sidney, 2000 and Westerlund-Wikstrom, 2000), the flap-tip helix protein is attached to a solid support and then libraries of compounds attached either to the outside of phage particles and genetically encoded in the corresponding phage genome, or attached to the outside of bacterial or yeast cells and genetically encoded in the corresponding bacterial or yeast genomes, are allowed to interact with the immobilized flap-tip helix protein. After suitable washing, the bound phage, bacteria, or yeast cells are recovered by gentle elution and the genetic information encoding the interacting molecule is recovered from them by conventional methods. These assays are particularly useful because the phage or cells recovered from one round of selection or counterselection can be amplified by growth in suitable conditions so that they can be subjected to multiple rounds of selection. It also is possible increase the stingency of the binding steps, or decrease the stringency of the counterselection steps, or to introduce a mutagenetic step in these growth steps so that the multiple rounds of selection and counterselection can serve to select out the phage or cells that encode molecules that bind the flap-tip helix bind with optimal properties. Proteins in which the flap-tip helix is deleted can serve as a useful counterscreen in these assays, for instance by exposing the selected phage or cells that are eluted from the first round of binding to an immobilized protein in which the flap-tip helix is mutated or deleted. Using this counterselection approach, phage or cells that stick to this control matrix could be discarded prior to proceeding to the next round of amplification and selection because they bind nonspecifically.
D. In Vitro Selection and Directed Evolution Assays
Potential lead compounds for creation of transcription inhibitors that target the flap-tip helix also could be created by in vitro selection of nucleic acids (RNA or DNA or other nucleic acids or nucleic-acid derivatives that can be replicated in vitro or in vivo) by repeated rounds of binding and replication of nucleic acids that adhere to an immobilized flap-tip helix protein (Szostak, 1997; Joyce, 1997). This method, sometimes referred to as SELEX (Gold et al., 1997) can generate novel compounds (sometimes referred to as aptamers; Brody and Gold, 2000) that inhibit RNA polymerase function by tightly binding the flap-tip helix. The counterselection strategy described above also could be used with SELEX strategies to discard nonspecifically binding compounds. These compounds can be used directly or can be used for design of similar molecules with improved properties. The aptamers could be particularly useful because they could be expressed inside bacterial cells when encoded by DNA or RNA such that activation of expression of the compounds inhibit growth of the bacteria or kill the bacteria.
E. mRNA Display Assay
Potential lead compounds for creation of transcription inhibitors that target the flap-tip helix also could be created by mRNA display technologies (Cho et al., 2000; Wilson et al., 2001). These methods allow generation of libraries of peptide aptamers of much greater complexity than is possible by phage display because the peptide aptamer is attached in vitro directly to the mRNA that encodes it, so that aptamers recovered after binding to an immobilized flap-tip helix protein carry with them the genetic information that can be replicated and used to synthesize additional aptamers. As with SELEX, these aptamers could potentially be subjected to multiple rounds of selection, replication, and even mutagenesis to evolve improved binding properties. The counterselection strategy described in section V.C also could be used with mRNA display strategies to discard nonspecifically binding compounds. Peptide aptamers discovered by this method could be used for design of similar molecules with improved properties. They also could be expressed inside bacterial cells when encoded by DNA or RNA such that activation of expression of the peptide aptamer or its derivatives would inhibit growth of the bacteria or kill the bacteria.
REFERENCES
-
- Amann et al., Gene, 69; 301 (1988).
- Artsimovitch and Landick, Genes Dev., 12, 3110 (1998).
- Artsimovitch and Landick, Proc. Natl. Acad. Sci. U.S.A., 97, 7090 (2000).
- Arthur and Brugess. J. Biol. Chem., 273, 31381 (1998).
- Arthur et al., J. Biol. Chem., 275, 23113 (2000).
- Borukhov et al., J. Biol. Chem., 266, 23921 (1991).
- Brody, E. N., and L. Gold. J Biotechnol., 74, 5 (2000).
- Burgess et al., Cold Spring Harb. Symp. Ouant. Biol., 63, 277 (1998).
- Callaci et al., J. Biol. Chem., 273, 32995, 1998.
- Callaci et al., Mol. Cell., 3, 229 (1999).
- Chamberlin and Hsu, In Regulation of Gene Expression in E. coli, E.C.C. Lin and A. S. Lynch, eds. (Austin: R. G. Landes Co.); pp. 7-25, 1996.
- Chan and Landick, J. Mol. Biol., 233, 25 (1993).
- Chan et al., J. Mol. Biol., 268, 54 (1997).
- Chen et al., Science, 265, 90 (1994).
- Cho et al. J Mol Biol., 297, 309 (2000).
- Cook, SPA: a revolutionary new technique for drug screening, Pharmaceutical Manufacturing International, 49-53, 1992
- Craig et al., J. Mol. Biol., 283, 741 (1998).
- Cramer et al., Science, 288, 640 (2000).
- Daube and von Hippel, Proc. Natl. Acad. Sci. U.S.A., 96, 8390 (1999).
- Davenport et al., Science, 287, 2497 (2000).
- Dombroski et al., Cell, 70; 501 (1992).
- Ennifar et al., J. Mol. Biol., 304, 35 (2000).
- Farnham and Platt, Cell, 20, 739 (1980).
- Fields and Stemglanz, Trends Genet., 10, 286 (1994).
- Finn et al., Embo J., 19, 6833 (2000).
- Fisher and Bumenthal, J. Biol. Chem., 255, 11056 (1980).
- Fu et al., Cell, 98, 799 (1999).
- Gardella et al., J. Mol. Biol., 206; 579 (1989).
- Gold et al., Proc Natl Acad Sci USA, 94, 59 (1997).
- Gross et al., J. Bacteriol., 128; 382 (1976).
- Gusarov and Nudler, Mol. Cell., 3, 495 (1999).
- Ingharn et al., Mol. Microbiol., 31, 651 (1999).
- Joyce, Science 276, 1658 (1997).
- Komissarova and Kashler, Proc. Natl. Acad. Sci. U.S.A., 94, 1755 (1997).
- Korzheva et al., Cold Spring Harb. Symp. Quant Biol., 63, 337 (1998).
- Korzheva et al., Science, 289, 619 (2000).
- Kumar et al., J. Mol. Biol., 235; 405 (1994).
- Lee and Landick, J. Mol. Biol., 228, 759 (1992).
- Liu et al., EMBO J., 15, 150 (1996).
- Lyakhov et al., J. Mol. Biol., 269, 28 (1997).
- Mah et al., Genes Dev., 14, 2664 (2000).
- Matsumoto et al., Bioorg Med Chem Lett., 10, 1857 (2000).
- Meisenheimer and Koch, Crit. Rev. Biochem. Mol. Biol., 32, 101 (1997).
- Mooney and Landick, Cell, 98, 687 (1999).
- Mote and Reines, J. Biol. Chem., 273, 16843 (1998).
- Mustaev et al., J. Biol. Chem., 266, 23927 (1991).
- Nudler et al., Cell, 89, 33 (1997).
- Nudler, J. Mol. Biol., 288, 1 (1999).
- Opalka et al., Proc. Natl. Acad. Sci. USA, 97; 617 (2000).
- Owens et al., Proc. Natl. Acad. Sci. U.S.A., 95, 6021 (1998).
- Owicki, J Biomol Screen., 5, 297-306 (2000).
- Pan et al., Proc. Natl. Acad. Sci. U.S.A., 96, 9545 (1999).
- Platt et al., In: RNA Structure and Function, Cold Spring Harbor Laboratory Press, pp. 541-574 (1997).
- Poglitsch et al., Cell, 98, 791 (1999).
- Richardson et al., J. Biol. Chem., 271, 1251 (1996).
- Richardson and Greenblatt, in Escherichia Coli and Salmonella, eds. Neidhardt et al. (ASM Press, Washington, D.C.) 2nd ed., pp. 822-848 (1996).
- Roberts, In: Regulation of Gene Expression in E. coli, R.G. Landes Co., Austin, Tex., pp. 2744 (1996).
- Ross et al., Science, 262, 1407 (1993).
- Sagitov et al., J. Biol. Chem., 268, 2195 (1993).
- Schauer et al., J. Mol. Biol., 194, 679 (1987).
- Severinov et al., J. Biol. Chem., 271, 27969, 1997.
- Severinova et al., J. Mol. Biol., 279; 9 (1998).
- Shilatifard, FASEB J., 12, 1437 (1998).
- Sidhu, Curr. Opin. Biotechnol., 11, 610 (2000).
- Sidorenkov et al., Mol. Cell, 2, 55 (1998).
- Siegele et al., J. Mol. Biol., 206; 591 (1989).
- Sigmund and Morgan, Biochemistry, 27, 5622 (1988).
- Sugimoto et al., Anal. Biochem., 179, 309 (1989).
- Szostak, Harvey Lect. 93, 95 (1997).
- Tavromina et al., J. Bacteriol., 178; 5263 (1996).
- Tomizawa et al., Genes Dev., 1, 217 (1987).
- Toulokhonov et al., Science, 292; 730 (2001).
- Uptain et al., Annu. Rev. Biochem., 6, 117 (1997).
- Wang et al., Proc. Natl. Acad. Sci. U.S.A., 94, 8433 (1997).
- Weilbaecher et al., Genes Dev., 8, 2913 1994.
- Westerlund-Wikstrom, Int. J. Med. Microbiol., 290, 223 (2000).
- Wilson et al., Proc Natl Acad Sci USA, 98, 3750 (2001).
- Yager and von Hippel, Biochemistry, 30, 1097 (1991).
- Yarnell and Roberts, Science, 284, 611 (1999).
- Zhang et al., Cell, 98, 811 (1999).
- Zheng et al., Proc. Natl. Acad. Sci. USA, 91, 7543 (1994).
All publications, patents and patent applications are incorporated herein by reference. While in the foregoing specification, this invention has been described in relation to certain preferred embodiments thereof, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details herein may be varied considerably without departing from the basic principles of the invention.
Claims
1. A method to identify one or more agents which inhibit or prevent the binding of a moiety to the flap-tip helix of the β subunit of core RNA polymerase, comprising:
- a) providing a complex formed by contacting the one or more agents with isolated core RNA polymerase, or an isolated β subunit of RNA polymerase or a portion thereof which comprises the flap-tip helix;
- b) contacting the complex with a moiety which specifically binds the flap-tip helix, wherein the moiety is a nucleic acid aptamer, a peptide aptamer or an initiation factor; and
- c) detecting or determining whether the one or more agents inhibit or prevent the binding of the moiety to the flap-tip helix.
2. A method to identify one or more agents which inhibit or prevent the binding of a moiety to the flap-tip helix of the β subunit of core RNA polymerase, comprising:
- a) providing a complex formed by contacting the one or more agents with a moiety which specifically binds the flap-tip helix, wherein the moiety is a nucleic acid aptamer, a peptide aptamer or an initiation factor;
- b) contacting the complex with isolated core RNA polymerase, or an isolated β subunit of RNA polymerase or a portion thereof which comprises the flap-tip helix; and
- c) detecting or determining whether the one or more agents inhibit or prevent the binding of the moiety to the flap-tip helix.
3. A method to identify one or more moieties which bind to the flap-tip helix, comprising:
- a) contacting a peptide comprising the flap-tip helix or a portion thereof with the one or more moieties; and
- b) detecting or determining whether the one or more moieties specifically bind to the flap-tip helix.
4. The method of claim 1, 2 or 3 wherein the moiety is a nucleic acid aptamer.
5. The method of claim 1, 2 or 3 wherein the moiety is a peptide aptamer.
6. The method of claim 1, 2 or 3 wherein the moiety is a prokaryotic protein.
7. The method of claim 3 wherein the moiety is a transcription factor.
8. The method of claim 7 wherein the transcription factor is an initiation factor.
9. The method of claim 7 wherein the transcription factor is an elongation factor.
10. The method of claim 1, 2 or 3 wherein moiety is σ.
11. The method of claim 10 wherein the initiation factor is σ70.
12. (canceled)
13. The method of claim 1, 2 or 3 wherein the portion includes residues corresponding to residues 900 to 909 of the β subunit of E. coli RNA polymerase.
14. The method of claim 1, 2 or 3 wherein the portion includes residues corresponding to residues 897 to 907 of the β subunit of E. coli RNA polymerase.
15. The method of claim 1, 2 or 3 wherein the portion includes residues corresponding to residues 830 to 1058 of the β subunit of E. coli RNA polymerase.
16. The method of claim 1 or 2 wherein core RNA polymerase, the β subunit or a portion thereof is labeled or is capable of being bound by a detectable label.
17. The method of claim 16 wherein a fluorophore is attached to or near the flap-tip helix.
18. The method of claim 16 wherein core RNA polymerase, the β subunit or portion thereof is capable of being bound by a labeled antibody.
19. The method of claim 1, 2 or 3 wherein the moiety is labeled or is capable of being bound by a detectable label.
20. The method of claim 19 wherein the moiety is capable of being bound by a labeled antibody.
21. The method of claim 3 wherein the peptide is labeled or is capable of being bound by a detectable label.
22. The method of claim 1 or 2 wherein fluorescence resonance energy transfer is employed to detect or determine whether the agent inhibits or prevents binding.
23. The method of claim 1 or 2 wherein luminescence resonance energy transfer is employed to detect or determine whether the agent inhibits or prevents binding.
24. The method of claim 1 or 2 wherein trypsin cleavage and SDS-PAGE are employed to detect or determine whether the agent inhibits or prevents binding.
25. The method of claim 1 wherein core RNA polymerase or the β subunit or portion thereof is attached to a solid substrate.
26. The method of claim 25 wherein the solid support comprises a scintillant and the moiety is radioactively labeled.
27. The method of claim 2 wherein the moiety is attached to a solid substrate.
28. The method of claim 27 wherein the solid support comprises a scintillant and core RNA polymerase, β subunit or portion thereof is radioactively labeled.
29. The method of claim 3 wherein the peptide is attached to a solid support.
30. The method of claim 29 wherein the solid support comprises a scintillant and the moiety is radioactively labeled.
31. The method of claim 3 wherein the one or more moieties are products encoded by a recombinant phage, virus, or cell.
32. The method of claim 1, 2 or 3 wherein a protease or nuclease is attached to or near the flap-tip helix.
33. The method of claim 1, 2 or 3 wherein a cross-linking moiety is attached to or near the flap-tip helix.
34. An agent identified by the method of claim 1 or 2.
35. A method to inhibit the growth of a prokaryotic cell, comprising:
- contacting the cell with an effective amount of the agent of claim 34.
36. An isolated and purified portion of the β subunit of RNA polymerase which binds to NusA or σ.
37. The isolated and purified portion of the β subunit of claim 36 which comprises a portion selected from the group consisting of residues corresponding to residues 830 to 1058, residues 897 to 907, and residues 900 to 909 of the β subunit of E. coli RNA polymerase.
38. A method to identify one or more agents that which inhibit or prevent the binding of a prokaryotic protein to the flap-tip helix of the β subunit of core RNA polymerase, comprising:
- a) contacting the one or more agents with a recombinant cell which expresses a first fusion polypeptide and a second fusion polypeptide, wherein the first fusion polypeptide comprises the flap-tip helix and a first polypeptide and the second fusion polypeptide comprises the prokaryotic protein or a fragment thereof which specifically binds the flap-tip helix and a second polypeptide, wherein the binding of the first polypeptide to the second polypeptide yields a detectable signal; and
- b) detecting or determining whether the one or more agents inhibits or prevents the signal.
39. The method of claim 38 wherein either the first or the second polypeptide comprises a DNA binding domain.
40. The method of claim 38 wherein either the first or the second polypeptide comprises an activation domain.
41. A moiety identified by the method of claim 3.
42. A method to identify one or more agents which inhibit or prevent transcription from a promoter that is dependent on a −35 sequence for activity, comprising:
- a) contacting the one or more agents with a composition for transcription comprising wild-type RNA polymerase and a first construct comprising a first promoter that is dependent on a −35 sequence to promote transcription and operably linked to an open reading frame for a gene; and
- b) identifying an agent that inhibits or prevents transcription from the first construct relative to transcription by wild-type RNA polymerase from a second construct comprising a second promoter that promotes transcription independent of the presence of a −35 sequence, which second promoter is operably linked to an open reading frame for a gene, thereby identifying an agent that inhibits or prevents transcription from a promoter that is dependent on a −35 sequence for activity.
43. The method of claim 42 wherein the one or more agents are contacted with a recombinant cell augmented with the first construct.
44. The method of claim 42 wherein the level of transcription from the first construct in the presence of the agent is substantially the same as the level of transcription by a mutant RNA polymerase comprising a mutant flap-tip helix from a third construct comprising a promoter that is dependent on a −35 sequence to promote transcription and operably linked to an open reading frame for a gene.
45. The method of claim 42 wherein the agent does not inhibit transcription by a mutant RNA polymerase comprising a mutant flap-tip helix from a third construct comprising a promoter that promotes transcription independent of the presence of a −35 sequence and operably linked to an open reading frame for a gene.
46. The method of claim 42 wherein the open reading frame in the first construct is an open reading frame for a marker gene or a selectable gene.
47. The method of claim 42 wherein the open reading frame in the second construct is an open reading frame for a marker gene or a selectable gene.
48. The method of claim 42 wherein the open reading frame in the first construct is different that the open reading frame in the second construct.
49. The method of claim 42 wherein the recombinant cell further comprises the second construct and wherein the open reading frame in the first construct is different that the open reading frame in the second construct
Type: Application
Filed: Apr 10, 2008
Publication Date: Aug 14, 2008
Applicant:
Inventors: Robert C. Landick (Madison, WI), Katherine M. Geszyain (Madison, WI), Irina E. Artsimovitch (Worthington, OH), Innokenti I. Toulokhonov (Madison, OH), Rachel A. Mooney (Madison, WI)
Application Number: 12/082,329
International Classification: C12Q 1/70 (20060101); C12Q 1/68 (20060101); G01N 33/567 (20060101); C12N 9/10 (20060101); C12N 1/20 (20060101); G01N 33/53 (20060101);